Clinical trial
Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer
NCT00116155 · Cell Genesys, Industry · Completed
Key facts
| NCT number | NCT00116155 |
|---|---|
| Title | Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer |
| Official title | A Phase I/II Dose Finding Trial of the Intravenous Injection of CV787, a Prostate-Specific Antigen Cytolytic Adenovirus, in Patients With Hormone Refractory Metastatic Prostate Cancer |
| Lead sponsor | Cell Genesys, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | CV787 (CG7870) |
| First posted | Jun 28, 2005 |
| Last update posted | Jun 28, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: